Clinical Trials
438 trialsNCT05064059 2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07284394 2026-05-26
PACHA-02
UNICANCER
Phase 3 Not yet recruiting
NCT07284849 2026-05-26
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT04230187 2026-05-22
TRIBE-C
Sun Yat-sen University
Phase 3 Active not recruiting
NCT05239741 2026-05-22
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT01150045 2026-05-19
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT07595276 2026-05-19
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3 Not yet recruiting
NCT05863195 2026-05-15
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT01269567 2026-05-14
GRECCAR 5
University Hospital, Bordeaux
Phase 3 Completed
NCT05652894 2026-05-14
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3 Active not recruiting
NCT02997228 2026-05-13
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03426371 2026-05-12
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Terminated
NCT07152821 2026-05-12
BATTMAN
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT04835142 2026-05-08
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Completed
NCT05673148 2026-05-08
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06662786 2026-05-08
OrigAMI-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06750094 2026-05-08
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07549412 2026-05-08
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
EMD Serono
Phase 3 Recruiting
NCT07228832 2026-05-05
HARMONi-GI3
Summit Therapeutics
Phase 3 Recruiting
NCT04793958 2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3 Active not recruiting
NCT05198934 2026-04-27
CodeBreak300
Amgen
Phase 3 Completed
NCT06252649 2026-04-24
CodeBreaK 301
Amgen
Phase 3 Recruiting
NCT07222800 2026-04-21
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
NCT07525206 2026-04-13
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
AbbVie
Phase 3 Not yet recruiting
NCT05253651 2026-04-07
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT01349881 2026-04-02
PACES
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT02343601 2026-04-02
PANEX3
University Hospital, Caen
Phase 3 Completed
NCT07018869 2026-03-31
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06497985 2026-03-19
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT00905047 2026-03-13
COLOCROSS
Centre Oscar Lambret
Phase 3 Completed
NCT02647099 2026-03-13
ALASCCA
Karolinska Institutet
Phase 3 Active not recruiting
NCT00102011 2026-03-09
00-046
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT04428905 2026-02-24
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
City of Hope Medical Center
Phase 3 Active not recruiting
NCT02945033 2026-02-18
ASPIK French
University Hospital, Rouen
Phase 3 Recruiting
NCT05171660 2026-02-17
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Active not recruiting
NCT03362177 2026-02-11
RECITE
Amgen
Phase 3 Completed
NCT02956876 2026-02-06
INCISIVE
University Hospital, Rouen
Phase 3 Completed
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07389265 2026-02-05
CAPRI-3 GOIM
University of Campania Luigi Vanvitelli
Phase 3 Recruiting
NCT06501482 2026-02-04
IRIMAD
Assistance Publique - HĂ´pitaux de Paris
Phase 3 Recruiting
NCT04854668 2026-01-30
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Active not recruiting
NCT07362836 2026-01-23
Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)
Fudan University
Phase 3 Not yet recruiting
NCT07361003 2026-01-22
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04457297 2026-01-21
ALTAIR
National Cancer Center Hospital East
Phase 3 Completed
NCT07340567 2026-01-14
CIRCULATEIII
UNICANCER
Phase 3 Not yet recruiting
NCT07320950 2026-01-06
Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients
Sun Yat-sen University
Phase 3 Completed
NCT07309289 2025-12-30
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 3 Recruiting
NCT06791512 2025-12-24
BASKETâ…˘
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT03869892 2025-12-22
SOLSTICE
Servier
Phase 3 Active not recruiting
NCT05008809 2025-12-12
AIO-KRK-0418
Charite University, Berlin, Germany
Phase 3 Recruiting